Andy Burnham has thrown his weight behind a pioneering British clinical trial that could accelerate the arrival of the first effective Alzheimer's treatments on the NHS, after his father Roy died from the disease.
The AD-SMART trial is designed to establish whether existing medicines can help with the poor memory and thinking problems that define dementia, and to determine which drugs might be fast-tracked into routine NHS care. Researchers are examining whether repurposed treatments — medicines already approved for other conditions — can tackle the symptoms of Alzheimer's, the most common cause of dementia.
Burnham, the mayor of Greater Manchester, welcomed the study as a significant step for patients and families affected by the condition. His support carries personal weight: his father Roy died from Alzheimer's, and the mayor has previously spoken about the toll the illness takes on relatives as well as those diagnosed.
The trial's central aim is to shorten the path between promising laboratory findings and treatments available to patients. By testing drugs that are already in use for other purposes, researchers hope to bypass some of the lengthy development and approval stages that new compounds must pass through, potentially delivering results to the NHS more quickly than conventional drug development allows.
Dementia is one of the leading causes of death in the United Kingdom, and successive governments have faced pressure to improve diagnosis, care and research funding. Campaigners have long argued that the country needs faster routes to treatment, particularly as the number of people living with Alzheimer's continues to rise with an ageing population.
The AD-SMART study is being described as a world-first effort of its kind, reflecting a growing international interest in drug repurposing as a way to address conditions that have so far resisted effective treatment. If the trial demonstrates benefits for memory and thinking, it could reshape how the health service approaches dementia care and open the door to earlier intervention for patients.
For families, the significance lies in the possibility of treatments that address the underlying symptoms rather than only managing the consequences of the disease. Burnham's endorsement adds a prominent political voice to calls for the trial's findings to be taken seriously by health officials and for the NHS to be ready to adopt any treatments that prove effective.
The trial's progress will be watched closely by clinicians, researchers and patient groups, who see it as a test of whether existing medicines can be turned into a practical answer to one of the most pressing health challenges facing Britain.